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Myocardial Effective Transverse 
Relaxation Time T2* is Elevated in 
Hypertrophic Cardiomyopathy: A 
7.0 T Magnetic Resonance Imaging 
Study
Till Huelnhagen  1, Min-Chi Ku  1,2, Henning Matthias Reimann1, Teresa Serradas Duarte1, 
Andreas Pohlmann1, Bert Flemming3, Erdmann Seeliger3, Christina Eichhorn4,  
Victor A. Ferrari5, Marcel Prothmann2,6, Jeanette Schulz-Menger2,6 & Thoralf Niendorf1,2,7
Hypertrophic cardiomyopathy (HCM) is the most common genetic disease of the myocardium and bares 
the risk of progression to heart failure or sudden cardiac death. Identifying patients at risk remains an 
unmet need. Recognizing the dependence of microscopic susceptibility on tissue microstructure and 
on cardiac macromorphology we hypothesized that myocardial T2* might be altered in HCM patients 
compared to healthy controls. To test this hypothesis, myocardial T2*-mapping was conducted at 
7.0 Tesla to enhance T2*-contrast. 2D CINE T2*-mapping was performed in healthy controls and HCM 
patients. To ensure that T2* is not dominated by macroscopic magnetic field inhomogeneities, volume 
selective B0 shimming was applied. T2* changes in the interventricular septum across the cardiac cycle 
were analyzed together with left ventricular radius and ventricular septal wall thickness. The results 
show that myocardial T2* is elevated throughout the cardiac cycle in HCM patients compared to 
healthy controls. A mean septal T2* = 13.7 ± 1.1 ms (end-systole: T2*,systole = 15.0 ± 2.1, end-diastole: 
T2*,diastole = 13.4 ± 1.3 ms, T2*,systole/T2*,diastole ratio = 1.12) was observed in healthy controls. For HCM 
patients a mean septal T2* = 17.4 ± 1.4 ms (end-systole: T2*,systole = 17.7 ± 1.2 ms, end-diastole: 
T2*,diastole = 16.2 ± 2.5 ms, T2*,systole/T2*,diastole ratio = 1.09) was found. Our preliminary results provide 
encouragement that assessment of T2* and its changes across the cardiac cycle may benefit myocardial 
tissue characterization in HCM.
Hypertrophic cardiomyopathy (HCM) is the most common genetic disease of the myocardium1. Epidemiological 
studies estimated the prevalence of HCM to be about 0.2–0.5% in the general population1,2. The disease is charac-
terized by myocardial hypertrophy in absence of an obvious extrinsic cause such as pressure or volume overload3. 
Patients often remain asymptomatic, but the disease can have a severe outcome in a subgroup of patients where 
it may cause heart failure and unexpected sudden cardiac death (SCD) in any age group. Major basic research 
efforts and clinical science activities are underway to better characterize HCM patient populations4.
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Cardiovascular magnetic resonance (CMR) imaging has emerged as an indispensable tool in the diagnosis and 
risk stratification of HCM3,5–7. Vigorous research has resulted in an enormous body of literature that documents 
the merits of CMR and showed that the degree of hypertrophy or presence of myocardial fibrosis are associated 
with a poor outcome in HCM8–11. Notwithstanding this success, understanding the pathophysiologic mechanisms 
of the imaging findings and identifying patients at risk of SCD or progression to heart failure remains an unmet 
clinical need4. So far it has been extremely challenging to connect the molecular and cellular defects that charac-
terize HCM to the level of major organ systems at which they play themselves out.
Quantitative mapping of the effective transversal relaxation time T2* provides valuable means for myocardial 
tissue characterization without the need for exogenous contrast12,13. A growing number of reports refers to map-
ping T2* in basic research and emerging clinical CMR applications14,15. Myocardial T2* is commonly assumed to 
provide a surrogate for myocardial tissue oxygenation14. Yet, the factors influencing T2* are of multiple nature16. 
Further to blood oxygenation, blood volume fraction per tissue volume, hematocrit, the oxyhemoglobin dissoci-
ation curve, main magnetic field inhomogeneities, tissue pH, tissue susceptibility, tissue iron content and tissue 
microstructure or micromorphology were reported to govern T2* 13,17,18. Cardiac macromorphology including 
ventricular radius and ventricular wall thickness constitutes another category of physiological parameters that 
orchestrate T2* 19.
The linear relationship between magnetic field strength and microscopic susceptibility effects renders ultra-
high field (B0 ≥ 7.0 T) CMR conceptually appealing for myocardial T2* mapping20,21. The enhanced susceptibility 
effects at 7.0 Tesla (T) may be useful to lower the detection level and to extend the dynamic range of the sensitivity 
for monitoring T2* changes19. Moving to ultrahigh magnetic fields also enables cinematic T2* mapping in scan 
times feasible for breath held acquisitions22. Taking advantage of this gain, temporally resolved T2* mapping at 
7.0 T showed cyclic changes of myocardial T2*, demonstrated a close correlation with myocardial wall thickness 
and myocardial wall stress and suggested an association with alterations in myocardial blood volume fraction 
across the cardiac cycle23. These findings hold the potential to exploit T2* mapping for non-invasive probing of 
myocardial (patho)physiology in vivo24.
It is established in the literature that HCM can cause alterations in the microstructure of myocardial tissue and 
can induce changes in cardiac macromorphology including myocardial wall thickening and reduction in left ven-
tricular inner radius. Based on the dependence of microscopic magnetic field pertubations on such changes25,26 
we hypothesize, that myocardial T2* and its time course across the cardiac cycle might be altered in HCM patients 
compared to healthy controls and hence might provide an imaging based marker for HCM. To test this hypothesis 
myocardial T2* of the intraventricular septum was examined at 7.0 Tesla using high spatio-temporally resolved, 
susceptibility weighted 2D CINE techniques in healthy controls and in HCM patients. This approach was paral-
leled by an assessment of the patterns and degree of myocardial hypertrophy.
Methods
Study population. Six healthy volunteers without any known history of cardiac disease (4 male, 
age = 50.0 ± 12.4 years (mean ± sd), BMI = 23.9 ± 2.9 kg/m2) and six patients with confirmed HCM (4 male, 
age = 52.7 ± 17.5 years (mean ± sd), BMI = 25.2 ± 1.9 kg/m2) were included in the study (Table 1) after due 
approval by the local ethical committee (ethics committee name: Ethikkommission der Charité, Ethikkommission 
1 am Campus Charité-Mitte, Berlin, Germany; registration number DE/CA73/5550/09, Landesamt für 
Arbeitsschutz, Gesundheitsschutz und technische Sicherheit, Berlin, Germany). In vivo studies were approved 
by the local ethical committee. The diagnosis of HCM was based on clinical parameters including echocardiog-
raphy3. Informed written consent was obtained from each volunteer prior to the study in compliance with the 
local institutional review board guidelines. All experiments were performed in accordance with the Declaration 
of Helsinki and the local institutional review board guidelines.
Late Gadolinium enhancement imaging. All HCM patients included in the study had previously under-
gone a clinical MRI exam including LGE imaging for detection of myocardial fibrosis27. For this purpose a 3.0 T 
MR system (Magnetom Verio, Siemens, Erlangen, Germany) was employed using a 32-channel RF receive array. 
LGE images were acquired 10–15 minutes after application of gadobutrol (0.2 mmol/kg body weight) using a 
FLASH inversion recovery gradient echo technique to detect fibrosis. Imaging parameters were: TE = 5.4 ms, 
TR = 10.5 ms, flip angle 30°, spatial resolution (1.5 × 1.5 × 6.0) mm3. LGE imaging at 3.0 T was performed for five 
of the six patients. For the sixth patient LGE imaging data were available from a 1.5 T system (Magnetom Avanto, 
Siemens, Erlangen, Germany). The slice planning during the current study was based on the previous clinical 
exams and carefully adjusted to achieve the same slice positioning.
B0 shimming. To minimize the influence of macroscopic magnetic field inhomogeneities on T2* and to 
ensure that T2* is not dominated by macroscopic magnetic field inhomogeneities but rather governed by micro-
scopic susceptibility effects, volume selective B0 shimming was carefully carried out prior to T2* mapping23. A B0 
field map was acquired in a single breath hold in end-diastole using an axial stack of slices covering the entire 
heart. A cardiac triggered multi-echo gradient-echo technique (TEs = 2.04 ms and 4.08 ms, TR = 5.4 ms, spatial 
resolution (4.2 × 4.2 × 8.0) mm3, 18 slices) was employed. Based on this field map second order shimming was 
applied for a shim volume accommodating a four chamber view and a mid-ventricular short axis view of the 
heart23. This shimming approach yielded magnetic field homogeneity in the heart comparable to what has been 
reported at 3.0 T22.
CINE imaging and T2* weighted image acquisition at 7.0 T. Experiments were performed in a 7.0 
T whole body MR system (Magnetom, Siemens, Erlangen, Germany). A 16 channel transceiver RF coil array 
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was used28. An MR stethoscope (EasyACT, MRI.TOOLS GmbH, Berlin, Germany)29 and pulse oximetry were 
employed for cardiac triggering and gating.
High spatial resolution CINE T2* mapping was performed with a segmented multi-shot multi breath hold 
gradient echo technique22 using: TE = 2.04–10.20 ms, ΔTE = 1.02 ms, TR = 12.16 ms, spatial resolution 
(1.1 × 1.1 × 4.0) mm3, flip angle 20°, GRAPPA acceleration factor 4. T2* weighted CINE acquisitions were split 
in three sub-acquisitions, each acquired in one breath-hold22 (Fig. 1I). High blood-myocardium contrast 2D 
CINE FLASH acquisitions (spatial resolution (1.4 × 1.4 × 4.0) mm3, flip angle 32°, TE = 2.67 ms, TR = 5.66 ms, 
GRAPPA acceleration factor 2) were used as anatomic reference. Mid-ventricular short axis views were acquired.
Data processing. Data processing (Fig. 1) was performed offline using MATLAB (The Mathworks, Natick, 
MA, USA) routines. Prior to T2* fitting, all T2* sensitized images were de-noised using a spatially adaptive 
non-local means (SANLM) filter30,31 (VBM8 toolbox (http://dbm.neuro.uni-jena.de/vbm8/)). SANLM filter-
ing decreased the estimated fit standard deviation of T2* in the myocardium by approximately 32% in healthy 
volunteers and 46% in patients in comparison to fits from unfiltered images. No artifacts due to filtering were 
observed in the fitted maps23,31. After de-noising, the T2* weighted CINE images from the three breath holds were 
co-registered employing a non-rigid registration provided by the MIRT MATLAB toolbox (https://sites.google.
com/site/myronenko/research/mirt). Images of the three registered scans were combined to form multi-echo 
series covering nine echoes with increasing T2* weighting (Fig. 1II). Subsequently, non-linear T2* fitting was 
performed using the MATLAB trust region algorithm in combination with a mono-exponential signal decay 
model (Fig. 1III). Goodness-of-fit was evaluated by R2. Additionally the fit standard deviation (T2*-STD) was 
estimated32. Voxels with decreased fit quality (R2 < 0.7 or T2*-STD > 3 ms) or unnaturally high/low T2* (T2* ≤ 1 or 
T2* ≥ 50 ms) were considered unreliable and excluded from further analysis.
Data analysis. For each subject the left ventricular (LV) myocardium was manually segmented for all car-
diac phases. LV wall thickness and inner radius were calculated for 2.5° wide radial sections covering the whole 
myocardium. This procedure was executed for all cardiac phases resulting in a total sample size of 18720 sections 
for the healthy controls and in 17712 sections for the HCM patients. Median T2* and mean wall thickness were 
calculated for each cardiac phase to allow assessment of temporal changes. For this purpose only the anteroseptal 
and inferoseptal segments33 (6326 septal sections in controls and 5904 sections in HCM patients) were consid-
ered, because T2* measurements have been shown to be most reliable in the ventricular septum20 (Fig. 1IV). Mean 
inner LV radius was calculated per phase by averaging over all sections. The averaged values of T2*, wall thickness 
and LV radius per cardiac phase were determined for all subjects. For calculation of group averages cardiac cycle 
duration was normalized and the number of phases was unified using linear interpolation. The overall distribu-
tion of septal T2* was analyzed using the histogram of the relative frequencies of T2* for all septal voxels in all 
subjects within the respective group. Evaluation of LV-morphology was described recently27.
Statistical analysis. Statistical analysis was performed using R34 and MATLAB. Continuous data are 
expressed as mean ± SD. Group differences were analyzed for significance using a student’s t-test for normally 
Parameter HCM Patients Healthy Controls P Value
n 6 6
Sex (male/female) 4/2 4/2
Age, y 52.7 ± 17.5 50 ± 12.4 0.77
Height, cm 170 ± 10 172 ± 8 0.71
Weight, kg 73.12 ± 9.6 71.5 ± 14.1 0.82
BMI, kg/m2 25.19 ± 1.9 23.9 ± 2.9 0.39
BSA, m2 1.84 ± 0.18 1.84 ± 0.21 0.97
Systolic blood pressure, mmHG 142.3 ± 22.8 135.5 ± 14.9 0.56
Diastolic blood pressure, mmHG 85.8 ± 17.5 86.3 ± 13.6 0.96
Heart rate, min−1 65.17 ± 10.83 71.7 ± 9.8 0.30
Mean end-systolic septal wall thickness, mm 16.6 ± 1.8 9.8 ± 1.4 0.001*
Mean end-diastolic septal wall thickness, mm 13.0 ± 3.1 6.2 ± 1.2 0.002*
Mean T2* averaged across all phases, ms 17.4 ± 1.4 13.7 ± 1.1 0.001*
Mean end-systolic septal T2*, ms 17.7 ± 1.2 15.0 ± 2.1 0.025*
Mean end-diastolic septal T2*, ms 16.2 ± 2.5 13.4 ± 1.3 0.039*
LVEDV, ml 128.8 ± 33.3 121.02 ± 21.88 0.64
LVESV, ml 51.3 ± 20.0 49.35 ± 12.96 0.85
LVEF 60.9 ± 8.5 59.3 ± 6.3 0.47
LV mass, g 168.9 ± 68.0 93.1 ± 17.0 0.041*
Presence of late gadolinium enhancement 6/6 —
Table 1. Subject characteristics. Values are given as mean ± standard deviation. The P value stems from a 
student’s t-test except for LVEF where it stems from a Mann-Whitney u-test. BMI, body mass index; BSA, body 
surface area; *P < 0.05.
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distributed data and a Mann-Whitney u-test otherwise. Normal distribution was verified using a Shapiro-Wilk 
test. P values of P < 0.05 were considered significant.
Availability of data. The datasets used and/or analysed during the current study are available from the cor-
responding author on reasonable request.
Figure 1. Image acquisition, post processing and data analysis pipeline. (I) Multi echo CINE image series 
are acquired, (II) de-noised, co-registered and combined. (III) Myocardium is segmented in 2.5° wide radial 
sections covering the whole myocardium and T2* mapping is performed. (IV) Finally basic cardiac morphology 
and septal T2* are being analyzed.
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Results
Assessment of cardiac morphology. All scans could be performed without any complication. Mean exami-
nation time for the assessment of cardiac morphology was 22 ± 7 minutes in healthy volunteers and 21 ± 2 minutes in 
patients. Ample blood myocardium contrast with a contrast-to-noise-ratio of about 55, image sharpness and signal uni-
formity across the heart were achieved for all subjects. Mean septal wall thickness (SWT) averaged over all subjects for 
all cardiac phases was found to be 7.3 ± 1.2 mm in healthy controls and 14.1 ± 2.5 mm in HCM patients. For end-systole 
mean SWT was 9.8 ± 1.4 mm in healthy controls compared to 16.6 ± 1.8 mm in HCM patients (Table 1). LV analysis 
confirmed the substantial difference in LV-mass between healthy volunteers (93 ± 17)g and HCM patients (169 ± 68)
g (P = 0.04). No significant differences in left ventricular end-diastolic volume (LVEDV) (P = 0.64), left ventricular 
end-systolic volume (LVESV) (P = 0.85) and left ventricular ejection fraction (LVEF) (P = 0.47) were found.
CINE T2* mapping. All volunteers and patients tolerated the breath-hold 2D CINE T2* mapping acqui-
sitions (mean examination: 1:28 ± 0:19 minutes in healthy volunteers and 1:26 ± 0:13 minutes in patients). B0 
shimming resulted in macroscopic field dispersions of ΔB0 < 3 Hz per mm (in-plane) and ΔB0 < 1 Hz per mm 
(through-plane) in the ventricular septum which is similar to what has been previously reported for cardiac MRI 
at 7.0 T and 3.0 T indicating, that T2* was not dominated by macroscopic magnetic field variations22,23.
Averaging T2* over all healthy controls for all cardiac phases (6323 septal sections) revealed a mean 
T2* = 13.7 ± 1.1 ms (Table 1). Figure 2 surveys LV T2* maps obtained for all healthy volunteers during systole and 
diastole. For this cohort a mean septal T2* = 15.0 ± 2.1 ms was observed for end-systole. For end-diastole mean 
septal T2* = 13.4 ± 1.3 ms was determined. The T2*,systole/T2*,diastole ratio was 1.12 for healthy subjects. The mean 
range (max – min) of T2* over the cardiac cycle was 4.0 ± 1.2 ms which is significantly higher (P < 0.01) than the 
0.7 ± 0.4 ms T2* change attributed to the periodic macroscopic B0 variation23.
In comparison, averaging T2* over all HCM patients and for all cardiac phases (5904 septal sections) revealed 
mean septal T2* = 17.4 ± 1.4 ms (Table 1, Fig. 3) which was significantly higher (P < 0.001) than in healthy con-
trols. For patients mean septal T2* was 17.7 ± 1.2 ms at end-systole and 16.2 ± 2.5 ms at end-diastole (Fig. 2). The 
T2*,systole/T2*,diastole ratio was 1.09. No significant difference was found for the mean range (max – min) of T2* over 
the cardiac cycle compared to controls (T2*(max-min) = 3.8 ± 1.2 ms).
Figure 2. Mid ventricular short axis view of systolic and diastolic myocardial T2* maps of healthy controls (top) 
and HCM patients (bottom) derived from CINE T2* mapping superimposed to FLASH CINE images. Spatial 
resolution = (1.0 × 1.0 × 4.0)mm3. T2* differences between systole and diastole can be observed. Distinct regions 
of increased T2* can be identified in the patients.
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Figure 3 highlights the time course of mean septal wall thickness, median septal T2* and mean inner ventricu-
lar radius over the cardiac cycle for HCM patients and healthy controls. Cyclic T2* changes across the cardiac 
cycle were found. A T2* increase during systole which is paralleled by an increase in the SWT and a decrease in 
the left-ventricular radius was observed for healthy controls and HCM patients. Also a decrease of T2* during 
diastole was noted for healty controls and for HCM patients. The overall shape of the curves was similar for 
patients and controls, with the the diastolic T2* decrease being less pronounced in patients. Plotting mean septal 
T2* against mean septal wall thickness revealed two clearly separable clusters for HCM patients and normal con-
trols (Fig. 4a). Analysis of the overall distribution of T2* across all septal sections and all cardiac phases showed a 
significant increase of T2* in patients compared to healthy controls (Fig. 4b).
Discussion
This study sought to test the hypothesis, that myocardial T2* and its time course across the cardiac cycle are altered 
in HCM patients compared to healthy controls. The main finding of this study is that septal T2* is significantly 
elevated in HCM patients versus healthy controls. Cyclic variations of T2* across the cardiac with T2* increasing in 
systole and decreasing in diastole were observed in both, healthy controls and HCM patients with similar ratios 
of T2*,systole/T2*,diastole of about 1.1. This is in line with previous reports on healthy volunteers23. These novel insights 
advance the capabilities of MR imaging based myocardial tissue characterization at a level of non-invasive inter-
rogation not previously available in humans.
Following previous reports suggesting myocardial blood oxygenation level dependent contrast or describing 
T2* as a surrogate for tissue oxygenation would lead to the conclusion that T2* prolongation in HCM can be 
attributed to an increase in oxygen supply in hypertrophic versus healthy myocardium. This interpretation does 
not match the present knowledge though. Previous studies demonstrated that T2* strongly depends not only on 
blood oxygenation but also on the tissue blood volume fraction16,23,35. Cyclic changes in myocardial tissue blood 
volume fraction which are a known physiologic phenomenon related to the contraction and relaxation of the 
cardiac muscle36 have been suggested as the main cause behind perodic variations of myocardial T2* across the 
cardiac cycle in healthy volunteers23. It is fair to assume, that the periodic changes of T2* observed in the HCM 
patient group are caused by the same mechanism. But how can the overall T2* increase in the patient cohort be 
explained? Microvascular dysfunction and subsequent ischemia are a known feature in HCM37 and have been 
reported to scale with greater degrees of hypertrophy and the presence of fibrosis38,39. Along this line Johansson 
et al. described a 33% decrease in myocardial capillary density in HCM40. A reduction of vascularity in presence 
Figure 3. Temporal changes of ventricular septal T2*, wall thickness and inner left ventricular radius plotted 
over the cardiac cycle in healthy volunteers and HCM patients. Group analysis for six healthy volunteers and 
six patients. Shaded regions indicate SEM. Septal T2* changes periodically over the cardiac cycle. Septal T2* is 
significantly increased in HCM patients.
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of scar tissue, which is also found in HCM patients, has been shown by histologic studies41,42. These conditions 
result in a reduced myocardial blood volume fraction in HCM and consequently decrease the impact of the deox-
ygenated hemoglobin on T2*, which could explain the observed T2* prolongation in hypertrophic regions versus 
normal or remote myocardium.
An association between microvascular dysfunction and late gadolinium enhancement (LGE) has been 
described in HCM in the literature38,43. Chiribiri et al. reported a coincidence of mid-myocardial LGE with 
reduced resting state perfusion and greater degrees of hypertrophy44. LGE was also present in all HCM patients in 
the current study. This finding supports the hypothesis that the observed T2* increase might be related to micro-
vascular dysfunction. Reduced myocardial blood flow as observed in microvascular dysfunction and subsequent 
ischemia has been associated with an unfavorable outcome in HCM and suggested as a strong predictor of clinical 
deterioration and death37,39. This hints that myocardial T2* mapping might provide an element of risk stratifica-
tion in HCM. Arguably, increased myocardial T2 often coinciding with LGE has been described in HCM and was 
associated with inflammation and edema as well as ischemia and fibrosis45,46. A T2 increase would also result in 
elevated T2*, providing a further explanation for the observed results. Admittedly these interpretations cannot 
be ultimately proven at this point. Further investigations including animal models of HCM are required to better 
understand the relationship of MR parameter changes and underlying microstructural and pathophysiologic 
mechanisms which cannot be definitely verified in vivo. Yet, this study provides new insights and directions for 
further investigations which will help to link pathological processes to MR findings also in humans.
It is no secret that the increase of magnetic susceptibility effects at higher fields not only affects microscopic 
susceptibility changes of (patho)physiological origin but can also result in stronger macroscopic field distortions 
e.g. at air-tissue interfaces. This is often a concern about T2* mapping at high and ultrahigh fields. While careful 
B0 shimming is certainly of high importance for this, in fact, dedicated shimming techniques have been shown to 
provide B0 field uniformities in the heart at 7.0 T similar to what has been described at 3.0 T22,23. Further to this, 
an often overlooked benefit of performing T2* mapping at higher fields is the possiblity to invest the signal gain 
due to the higher net magnetization to realize smaller voxel sizes. This effectively reduces intravoxel dephasing 
due to macroscopic field gradients and their influence on T2* and also decreases partial volume effects. The voxel 
size used for T2* mapping in this study of (1.1 × 1.1 × 4.0) mm3 is multiple times smaller than voxel sizes com-
monly used for T2* mapping in at 1.5 T ot 3.0 T which further helps to reduce the impact of macroscopic field 
inhomogeneities22.
While we recognize a limitation due to the limited number of healthy subjects and patients studied, we believe 
this feasibility study to be an essential precursor to a larger 7.0 T study involving healthy and HCM patient 
cohorts. Such a study is needed to further elucidate the underlying causes for the reported T2* increase and fur-
ther analyze the temporal behavior of T2* over the cardiac cycle in health and in the presence of pathology.
We are only beginning to understand the meaning of the dynamics of T2* across the cardiac cycle, but the 
technique holds the promise to enable further insights into myocardial (patho)physiology in vivo. Admittedly, the 
continuous motion of the myocardium currently limits temporal T2* assessment to larger regions of interest like 
the septum which have to be defined for each cardiac phase. Application of motion compensation techniques to 
CINE T2* mapping data would enable us to derive information on T2* dynamics at single voxel level. Parameters 
like T2* temporal standard deviation, slope, time to peak, relative T2* change, etc. could be derived from such 
times series and converted to quantitative maps that may help to highlight areas of change and pathology. This 
approach provides an entirely new set of potential (patho)physiological imaging paramters but requires further 
efforts to be implemented and evaluated.
Figure 4. (a) Scatter plot of septal wall thickness and T2* in HCM patients and healthy controls at 7.0 T. Each 
marker corresponds to one cardiac phase. Errorbars indicate SEM. Two clusters for patients and for volunteers 
can clearly be separated using mean septal T2* and wall thickness. (b) Histogram (top) and cumulative 
frequency plot (bottom) of T2* in the mid ventricular septum. Combined data from six healthy volunteers and 
six HCM patients for all cardiac phases. A clear shift toward higher T2* can be observed in the HCM patients.
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Conclusions
Myocardial T2* is elevated throughout the cardiac cycle in HCM patients compared to healthy controls at 7.0 T. A 
reduction in tissue blood volume fraction in the hypertrophied myocardium and a T2 increase related to inflam-
matory processes were suggested as potential causes for this finding. These factors have been associated with a 
higher risk for a poor outcome of HCM patients. Our preliminary results provide encouragement, that assess-
ment of T2* and its changes across the cardiac cycle may benefit myocardial tissue characterization in hyper-
trophic cardiomyopathy.
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